イットリウム90
参考資料

↑  “The Half-Life of Yttrium-90”. Physical Review 93 (5):  1029. (February 1, 1954). Bibcode: 1954PhRv...93.1029C. doi:10.1103/physrev.93.1029. ISSN 0031-899X.
↑   DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Lippincott Williams & Wilkins. (1 April 2008). p. 2507. ISBN 978-0-7817-7207-5. https://books.google.com/books?id=yrBI5zx69X8C&pg=PA2507 9 June 2011閲覧。
1 2  “Y-90 Handling Precautions”. Berkeley Lab. 15 January 2018時点のオリジナルよりアーカイブ。2015年7月15日閲覧。
↑  “Live Chart of Nuclides”.   International Atomic Energy Agency (2009年). 2020年6月2日閲覧。
↑  Rault E, Vandenberghe S, Staelens S, Lemahieu T (2009). Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations. 4th European Conference of the International Federation for Medical and Biological Engineering. Vol. 22. Berlin, Heidelberg: Springer. pp. 500–504. ISBN 9783540892083. 2013年10月21日閲覧。
↑  d'Arienzo, Marco (2013). “Emission of β+ Particles Via Internal Pair Production in the 0+ – 0+ Transition of 90Zr: Historical Background and Current Applications in Nuclear Medicine Imaging”. Atoms 1 (1):  2–12. Bibcode: 2013Atoms...1....2D. doi:10.3390/atoms1010002.
↑  “Generator-produced yttrium-90 for radioimmunotherapy”. Journal of Nuclear Medicine 28 (9):  1465–70. (September 1987). PMID 3625298.
↑  “PNNL: Isotope Sciences Program - Yttrium-90 Production”.  PNNL (February 2012). 2012年10月23日閲覧。
↑  “Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry”. The British Journal of Radiology 89 (1062):  20150943. (June 2016). doi:10.1259/bjr.20150943. PMC 5258157. PMID 26943239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5258157/.
↑  “Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma”. Advances in Therapy 33 (5):  699–714. (May 2016). doi:10.1007/s12325-016-0324-7. PMC 4882351. PMID 27039186. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882351/.
↑  “Understanding SIR-Spheres Y-90 Resin Microspheres” (英語). Colorectal Cancer Alliance. 2019年10月21日閲覧。
↑  “Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma”. Gastroenterology 151 (6):  1155–1163.e2. (December 2016). doi:10.1053/j.gastro.2016.08.029. PMC 5124387. PMID 27575820. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124387/.
↑  “Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization”. Clinical Gastroenterology and Hepatology 11 (10):  1358–1365.e1. (October 2013). doi:10.1016/j.cgh.2013.04.028. PMID 23644386.
↑  “Theranostic Imaging of Yttrium-90”. BioMed Research International 2015:  481279. (2015-04-22). doi:10.1155/2015/481279. PMC 4464848. PMID 26106608. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464848/.
↑  Kao, Y. H.; Steinberg, J. D.; Tay, Y. S.; Lim, G. K.; Yan, J.; Townsend, D. W.; Takano, A.; Burgmans, M. C. et al. (2013). “Post-radioembolization yttrium-90 PET/CT - part 1: Diagnostic reporting”. Ejnmmi Research 3 (1):  56. doi:10.1186/2191-219X-3-56. PMC 3726297. PMID 23883566. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726297/.